Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04351360
Other study ID # C19-26
Secondary ID 2020-A00166-33
Status Not yet recruiting
Phase
First received
Last updated
Start date April 10, 2020
Est. completion date April 10, 2021

Study information

Verified date February 2020
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact Aurélie Méneret, MD, PhD
Phone +33 1 42 16 24 61
Email aurelie.meneret@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Heterozygous mutations in the ADCY5 gene cause involuntary early-onset hyperkinetic movements. In addition, patients may have associated psychiatric disorders.There is currently no treatment. As the pathophysiology is linked to ADCY5 hyperactivity, the investigative team has treated patients with caffeine, an antagonist. The investigator wishes to interview patients on the effect of caffeine on their motor symptoms and their overall clinical condition, and on the possible existence of psychiatric comorbidities using phone questionnaires.


Description:

Heterozygous mutations in the ADCY5 gene cause involuntary early-onset hyperkinetic movements. The phenotype combines chorea, dystonia and / or myoclonus with frequent facial involvement, axial hypotonia, fluctuations and / or episodes of paroxysmal dyskinesia which can be nocturnal and / or painful.

Many treatments have been tried, with no obvious efficacy. Two patients from the same family (a father and daughter) told investigators that caffeine had a dramatic effect on their paroxysmal episodes. They said that taking coffee would prevent episodes and reduce their duration (efficacy estimated at 80%), an effect specific to caffeine since it was reproduced by the ingestion of caffeine citrate capsules. Very interestingly, there is a rationale underlying this phenomenon. Indeed, caffeine is an antagonist of the adenosine A2A receptors (A2AR), receptors which activate ADCY5 and which are localized preferentially in striatal neurons expressing dopamine D2 receptors. As caffeine is an A2AR antagonist, it likely inhibits ADCY5, and therefore induces clinical improvement in patients with hyperactivity of this protein.

In addition, the investigative team noted anxiety in some of its patients, and the question of the presence of psychiatric disorders in ADCY5 patients was recently raised in the literature.

The investigative team wishes to collect standardized preliminary data by questioning patients on the effect of caffeine on their motor symptoms and their overall clinical state, and on the possible existence of psychiatric comorbidities using structured questionnaires which will be carried out by phone.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date April 10, 2021
Est. primary completion date April 10, 2021
Accepts healthy volunteers No
Gender All
Age group 8 Years and older
Eligibility Inclusion Criteria:

- Proven genetic diagnosis of ADCY5-related dyskinesia

- Caffeine intake

- Non opposition by the patient or the legal representatives if the patient is a minor.

No Exclusion Criteria.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Institut National de la Santé Et de la Recherche Médicale, France

References & Publications (6)

Chen DH, Méneret A, Friedman JR, Korvatska O, Gad A, Bonkowski ES, Stessman HA, Doummar D, Mignot C, Anheim M, Bernes S, Davis MY, Damon-Perrière N, Degos B, Grabli D, Gras D, Hisama FM, Mackenzie KM, Swanson PD, Tranchant C, Vidailhet M, Winesett S, Trouillard O, Amendola LM, Dorschner MO, Weiss M, Eichler EE, Torkamani A, Roze E, Bird TD, Raskind WH. ADCY5-related dyskinesia: Broader spectrum and genotype-phenotype correlations. Neurology. 2015 Dec 8;85(23):2026-35. doi: 10.1212/WNL.0000000000002058. Epub 2015 Nov 4. — View Citation

Friedman JR, Méneret A, Chen DH, Trouillard O, Vidailhet M, Raskind WH, Roze E. ADCY5 mutation carriers display pleiotropic paroxysmal day and nighttime dyskinesias. Mov Disord. 2016 Jan;31(1):147-8. doi: 10.1002/mds.26494. Epub 2015 Dec 21. — View Citation

Lee KW, Hong JH, Choi IY, Che Y, Lee JK, Yang SD, Song CW, Kang HS, Lee JH, Noh JS, Shin HS, Han PL. Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. J Neurosci. 2002 Sep 15;22(18):7931-40. — View Citation

Méneret A, Gras D, McGovern E, Roze E. Caffeine and the Dyskinesia Related to Mutations in the ADCY5 Gene. Ann Intern Med. 2019 Jun 11. doi: 10.7326/L19-0038. [Epub ahead of print] — View Citation

Vijiaratnam N, Newby R, Kempster PA. Depression and psychosis in ADCY5-related dyskinesia-part of the phenotypic spectrum? J Clin Neurosci. 2018 Nov;57:167-168. doi: 10.1016/j.jocn.2018.08.049. Epub 2018 Aug 30. — View Citation

Yamada K, Kobayashi M, Kanda T. Involvement of adenosine A2A receptors in depression and anxiety. Int Rev Neurobiol. 2014;119:373-93. doi: 10.1016/B978-0-12-801022-8.00015-5. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of responders to caffeine the response being defined as an improvement of overall involuntary movements of 40% or more. one hour
Secondary Global change of involuntary movements ranging from 0 (no change) to 10 (disappearance of involuntary movements) evaluated by patients one hour
Secondary Global clinical change ranging from 0 (no change) to 10 (normalization of the global clinical state) evaluated by patients one hour
Secondary Change of the duration of paroxysmal episodes of movement disorders with caffeine evaluated by patients one hour
Secondary Frequency change of paroxysmal episodes of movement disorders with caffeine evaluated by patients one hour
Secondary Presence or absence of psychiatric symptoms according to the MINI (Mini International Neuropsychiatric Interview) one hour
See also
  Status Clinical Trial Phase
Completed NCT00986414 - Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease Phase 2
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Completed NCT05044572 - Comparison of Open Chain Kinetic Exercises and Forward Head Posture Correction in Type II Scapular Dyskinesia N/A
Completed NCT01474421 - Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease Phase 2
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Recruiting NCT05116813 - Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy Phase 2/Phase 3
Completed NCT01385592 - Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias Phase 2
Completed NCT01491932 - Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias Phase 2
Completed NCT00086294 - ACP-103 to Treat Parkinson's Disease Phase 2
Completed NCT00360568 - Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects Phase 3
Recruiting NCT05317390 - Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia N/A
Completed NCT03956979 - A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia Phase 2
Active, not recruiting NCT04453995 - A Follow-up of the Influencing Factors of Dyskinesia in Patients With Parkinson's Disease
Not yet recruiting NCT05516875 - Open-Label Extension Study of ASTORIA Phase 2
Terminated NCT02589340 - Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia Phase 1
Completed NCT00076674 - Levetiracetam Treatment of L-dopa Induced Dyskinesias Phase 2
Completed NCT00888186 - Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics Phase 4
Completed NCT00004576 - Study of LY300164 for the Treatment of Parkinson's Disease Phase 2
Completed NCT00036296 - Effects of Talampanel on Patients With Advanced Parkinson's Disease Phase 1/Phase 2
Completed NCT00363727 - Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's Phase 3